bluebird bio Prepares for Launch

bluebird bio's (NASDAQ:BLUE) second-quarter financial report was fairly mundane, with no drugs generating revenue. But that will change shortly, given the recent European approval of Zynteglo to treat a blood disease called beta-thalassemia.